Pavlick, Anna C

Publications

Sort by

Co-Author Network

selected publications

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer chemotherapy and pharmacology. 2023 Academic Article GET IT
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. European journal of cancer (Oxford, England : 1990). 2023 Academic Article GET IT
A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
A multidisciplinary management algorithm for brain metastases. Neuro-oncology advances. 2022 Review GET IT
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 5
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma research. 2022 Academic Article GET IT
Times cited: 2
Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. Journal of neuro-oncology. 2022 Academic Article GET IT
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. The Lancet. Oncology. 2021 Academic Article GET IT
Times cited: 71
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-oncology. 2021 Academic Article GET IT
Times cited: 49
Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma. Genome medicine. 2021 Academic Article GET IT
Times cited: 18
Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2021 Academic Article GET IT
Times cited: 17
Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID innovations : skin science from molecules to population health. 2021 Academic Article GET IT
Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma research. 2021 Academic Article GET IT
Times cited: 2
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 77
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma research. 2021 Academic Article GET IT
Times cited: 12
The State of Melanoma: Emergent Challenges and Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 27
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 47
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature cancer. 2020 Academic Article GET IT
Times cited: 38
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis. Future oncology (London, England). 2020 Academic Article GET IT
Times cited: 16
Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. Melanoma research. 2020 Academic Article GET IT
Times cited: 2
Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health. Oncology. 2020 Academic Article GET IT
Times cited: 2
Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. Journal of the National Cancer Institute. 2020 Academic Article GET IT
Times cited: 24
Current concepts and approaches to merkel cell carcinoma. Archives of dermatological research. 2020 Review GET IT
Times cited: 7
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. NPJ precision oncology. 2020 Academic Article GET IT
Times cited: 91
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 87
Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. Journal of surgical oncology. 2020 Academic Article GET IT
Times cited: 6
Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. Facial plastic surgery : FPS. 2020 Academic Article GET IT
Times cited: 7
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. Journal for immunotherapy of cancer. 2020 Review GET IT
Times cited: 29
TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. The Journal of investigative dermatology. 2020 Academic Article GET IT
Times cited: 14
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 32
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer immunology research. 2019 Academic Article GET IT
Times cited: 33
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome medicine. 2019 Academic Article GET IT
Times cited: 90
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. Journal for immunotherapy of cancer. 2019 Academic Article GET IT
Times cited: 57
Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). Scientific reports. 2019 Academic Article GET IT
Times cited: 4
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 30
Impact of initial stage on metastatic melanoma survival. Melanoma research. 2019 Academic Article GET IT
Times cited: 11
Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report. 2019 GET IT
Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2019 Review GET IT
Ipsilateral metastatic choroidal melanoma responds to systemic immunotherapy. 2019 GET IT
Times cited: 6
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. 2019 GET IT
Times cited: 45
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer immunology, immunotherapy : CII. 2019 Academic Article GET IT
Times cited: 31
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 53
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 Academic Article GET IT
Times cited: 41
Revolutionizing treatment of advanced melanoma with immunotherapy. Surgical oncology. 2019 Review GET IT
Times cited: 9
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future oncology (London, England). 2018 Review GET IT
Times cited: 25
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 784
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine. 2018 Academic Article GET IT
Times cited: 315
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. 2018 GET IT
Times cited: 47
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for immunotherapy of cancer. 2018 Academic Article GET IT
Times cited: 9
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Journal of translational medicine. 2018 Academic Article GET IT
Times cited: 81
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 14
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
Times cited: 132
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 24
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology. 2017 Review GET IT
Times cited: 18
Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma. 2017 GET IT
Times cited: 18
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer treatment reviews. 2017 Review GET IT
Times cited: 197
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology. 2017 Academic Article GET IT
Times cited: 5
Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. 2017 GET IT
Times cited: 80
Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. Journal of neurosurgery. 2017 Academic Article GET IT
Times cited: 46
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of immunotherapy (Hagerstown, Md. : 1997). 2017 Academic Article GET IT
Times cited: 16
MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis. The Journal of investigative dermatology. 2016 Letter GET IT
Times cited: 11
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 166
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Investigational new drugs. 2016 Academic Article GET IT
Times cited: 22
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 686
Metastatic Cutaneous Squamous Cell Carcinoma: The Importance of T2 Stratification and Hematologic Malignancy in Prognostication. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2016 Academic Article GET IT
Times cited: 11
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Investigational new drugs. 2016 Academic Article GET IT
Times cited: 78
Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. Journal of neuro-oncology. 2016 Academic Article GET IT
Times cited: 46
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 28
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. 2015 GET IT
Times cited: 1
Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Molecular oncology. 2015 Academic Article GET IT
Times cited: 57
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 1263
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 63
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 2177
Acral lentiginous melanoma of the foot misdiagnosed as a traumatic ulcer. A cautionary case. 2015 GET IT
Times cited: 7
Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma. 2015 GET IT
Times cited: 20
Identification of metastasis-suppressive microRNAs in primary melanoma. Journal of the National Cancer Institute. 2015 Academic Article GET IT
Times cited: 42
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer immunology research. 2015 Academic Article GET IT
Times cited: 72
Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of medical genetics. 2015 Academic Article GET IT
Times cited: 17
Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. Journal of translational medicine. 2014 Academic Article GET IT
Times cited: 19
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 74
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 212
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 50
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. European journal of cancer (Oxford, England : 1990). 2014 Academic Article GET IT
Times cited: 19
Update on vaccines for high-risk melanoma. Current treatment options in oncology. 2014 Review GET IT
Times cited: 10
Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?. Human pathology. 2014 Academic Article GET IT
Times cited: 11
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer journal (Sudbury, Mass.). 2014 Academic Article GET IT
Times cited: 43
Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo. Pharmaceuticals (Basel, Switzerland). 2013 Academic Article GET IT
Times cited: 810
Melanoma risk loci as determinants of melanoma recurrence and survival. Journal of translational medicine. 2013 Academic Article GET IT
Times cited: 29
Radiation-related cancer risk associated with radiographic imaging. JAMA ophthalmology. 2013 Letter GET IT
Impact of age on the management of primary melanoma patients. Oncology. 2013 Academic Article GET IT
Times cited: 12
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature reviews. Clinical oncology. 2013 Conference Paper GET IT
Times cited: 155
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 142
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma research. 2013 Academic Article GET IT
Times cited: 148
Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. The American journal of surgical pathology. 2013 Academic Article GET IT
Times cited: 31
Vemurafenib and radiation therapy in melanoma brain metastases. Journal of neuro-oncology. 2013 Academic Article GET IT
Times cited: 93
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 309
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 386
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer chemotherapy and pharmacology. 2012 Academic Article GET IT
Times cited: 37
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 112
Serum microRNAs as biomarkers for recurrence in melanoma. Journal of translational medicine. 2012 Academic Article GET IT
Times cited: 105
Targeted therapies for metastatic melanoma. Dermatologic clinics. 2012 Review GET IT
Times cited: 5
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (London, England). 2012 Academic Article GET IT
Times cited: 774
Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro-oncology. 2012 Academic Article GET IT
Times cited: 13
Histology-specific microRNA alterations in melanoma. The Journal of investigative dermatology. 2012 Academic Article GET IT
Times cited: 43
Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Academic Article GET IT
Times cited: 54
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1803
Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Oncology. 2012 Academic Article GET IT
Times cited: 3
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PloS one. 2012 Academic Article GET IT
Times cited: 243
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PloS one. 2011 Academic Article GET IT
Times cited: 60
Deletion of PTENP1 pseudogene in human melanoma. The Journal of investigative dermatology. 2011 Letter GET IT
Times cited: 79
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. British journal of cancer. 2011 Academic Article GET IT
Times cited: 95
A high proliferative index of recurrent melanoma is associated with worse survival. Oncology. 2011 Academic Article GET IT
Times cited: 17
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Academic Article GET IT
Times cited: 659
Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. Journal of community health. 2011 Academic Article GET IT
Times cited: 29
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer research. 2011 Academic Article GET IT
Times cited: 52
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Investigational new drugs. 2011 Academic Article GET IT
Times cited: 22
Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. 2011 GET IT
Times cited: 19
A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PloS one. 2010 Academic Article GET IT
Times cited: 83
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2010 Academic Article GET IT
Times cited: 85
Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment cell & melanoma research. 2010 Academic Article GET IT
Times cited: 44
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. Journal of translational medicine. 2010 Editorial Article GET IT
Times cited: 214
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 50
Mucosal melanomas: a case-based review of the literature. The oncologist. 2010 Review GET IT
Times cited: 76
Melanoma MicroRNA signature predicts post-recurrence survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 185
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PloS one. 2010 Academic Article GET IT
Times cited: 11
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 255
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 282
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC cancer. 2009 Academic Article GET IT
Times cited: 64
Novel therapeutics for melanoma. Expert review of anticancer therapy. 2009 Review GET IT
Times cited: 21
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy. 2009 Academic Article GET IT
Times cited: 19
Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 58
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 31
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer chemotherapy and pharmacology. 2009 Academic Article GET IT
Times cited: 24
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Academic Article GET IT
Times cited: 72
Meta-analysis of sentinel lymph node positivity in thin melanoma ( Cancer. 2009 Review GET IT
Times cited: 94
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American journal of translational research. 2009 Academic Article GET IT
Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer. 2008 Academic Article GET IT
Times cited: 73
Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. Journal of translational medicine. 2008 Academic Article GET IT
Times cited: 9
Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer research. 2008 Academic Article GET IT
Times cited: 47
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 16
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008 Academic Article GET IT
Times cited: 221
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 81
Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007 Academic Article GET IT
Times cited: 83
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer immunity. 2007 Academic Article GET IT
Times cited: 97
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 261
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. The Journal of molecular diagnostics : JMD. 2007 Academic Article GET IT
Times cited: 30
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. Journal of translational medicine. 2007 Academic Article GET IT
Times cited: 28
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 548
Whole body PET/CT for initial staging of choroidal melanoma. The British journal of ophthalmology. 2005 Academic Article GET IT
Times cited: 91
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 85
Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases. 2005 GET IT
Times cited: 11
Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. American journal of ophthalmology. 2005 Academic Article GET IT
Times cited: 47
PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 77
Innovations in the treatment of melanoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Whole body PET/CT imaging for detection of metastatic choroidal melanoma. The British journal of ophthalmology. 2004 Letter GET IT
Times cited: 23
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor. Anti-cancer drugs. 2004 Academic Article GET IT
Times cited: 10
Novel therapeutic agents under investigation for malignant melanoma. Expert opinion on investigational drugs. 2003 Review GET IT
Times cited: 14
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anti-cancer drugs. 2003 Academic Article GET IT
Times cited: 6
Treatment of sarcomas: thinking out-of-the-box. Cancer investigation. 2003 Editorial Article GET IT
Chemotherapy approaches to melanoma. Dermatologic clinics. 2002 Review GET IT
Times cited: 7
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas. American journal of clinical oncology. 2002 Academic Article GET IT
Times cited: 8
Ewing sarcoma in an octogenarian: a case report. 2002 GET IT
Times cited: 5
Immunoproliferative small intestinal disease: case report and literature review. Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians. 1999 Review GET IT
Times cited: 3
Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 63

more ...

less ...

Background

education and training

M.B.A., Columbia Business School, Columbia University 2017
D.O., Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey 1990
M.Sc., Fairleigh Dickinson University 1990
B.S.N., Fairfield University 1984

Contact

full name

Anna C Pavlick

primary email

acp9008@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Anna C Pavlick Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage